Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.81 |
| ▸ | MAPT | P10636 | 6/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.60 |
| ▸ | RELA | Q04206 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14097123 | 0.92 | MAPT (0.78) | ALDH1A1MAPTMAPK1GAAPOLB | |
| SCHEMBL2853236 | 0.87 | ALDH1A1 (0.73) | ALDH1A1MAPTMAPK1GAAPOLB | |
| SCHEMBL2856762 | 0.85 | ALDH1A1 (0.77) | ALDH1A1MAPTMAPK1GAAPOLB | |
| SCHEMBL14097124 | 0.85 | ALDH1A1 (0.67) | ALDH1A1MAPTMAPK1GAAPOLB | |
| SCHEMBL13593554 | 0.85 | ALDH1A1 (0.63) | ALDH1A1MAPTMAPK1GAAPOLB | |
| SCHEMBL14097125 | 0.84 | ALDH1A1 (0.67) | ALDH1A1MAPTMAPK1GAAPOLB | |
| SCHEMBL14097120 | 0.84 | ALDH1A1 (0.64) | ALDH1A1MAPTMAPK1GAAPOLB | |
| SCHEMBL773204 | 0.84 | NR4A3 (0.78) | ALDH1A1MAPTMAPK1GAAPOLB | |
| SCHEMBL14097104 | 0.83 | ALDH1A1 (0.64) | ALDH1A1MAPTMAPK1GAAPOLB | |
| SCHEMBL14097112 | 0.82 | ALDH1A1 (0.63) | ALDH1A1MAPTMAPK1GAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | disclosed |
| US-7414056-B2 | Pyrazole-amide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414056-B2 | Pyrazole-amide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-19 | — | — | US | disclosed |
| US-7390810-B2 | Pyrazole-amine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-24 | — | — | US | disclosed |
| US-7390810-B2 | Pyrazole-amine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-24 | — | — | US | disclosed |
| US-20080108626-A1 | (5-amino-1-phenyl-1H-pyrazole)-(3-Amino-N-isoxazol-3-yl-4-methyl)-benzamide; p38 mitogen-activated protein kinase inhibitor; reduced levels of TNF- alpha expression; antiinfammatory agent: rheumatoid arthritis, psoriasis, multiple sclerosis, endotoxin shock, osteoporosis, Alzheimer's disease | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080108626-A1 | (5-amino-1-phenyl-1H-pyrazole)-(3-Amino-N-isoxazol-3-yl-4-methyl)-benzamide; p38 mitogen-activated protein kinase inhibitor; reduced levels of TNF- alpha expression; antiinfammatory agent: rheumatoid arthritis, psoriasis, multiple sclerosis, endotoxin shock, osteoporosis, Alzheimer's disease | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108626-A1 | (5-amino-1-phenyl-1H-pyrazole)-(3-Amino-N-isoxazol-3-yl-4-methyl)-benzamide; p38 mitogen-activated protein kinase inhibitor; reduced levels of TNF- alpha expression; antiinfammatory agent: rheumatoid arthritis, psoriasis, multiple sclerosis, endotoxin shock, osteoporosis, Alzheimer's disease | MAPK1, MAPK3, TNF | ALDH1A1 4289/4885MAPT 256/4885MAPK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.